WallStreetZenWallStreetZen

NASDAQ: CPRX
Catalyst Pharmaceuticals Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Catalyst Pharmaceuticals revenue was $578.20M for the trailing 12 months ending Sep 30, 2025, with 43.2% growth year over year. Quarterly revenue for the quarter (Q3 2025) ending on Sep 30, 2025 was $148.4M, up 1.2% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, CPRX annual revenue was $491.7M, with 23.5% growth year-over-year.

CPRX past revenue growth

How has CPRX's revenue growth performed historically?

Company
25.56%
Industry
303.44%
Market
20.85%
CPRX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CPRX's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CPRX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CPRX revenue history

Current Revenue
$578.2M
Current Earnings
$217.6M
Current Profit Margin
37.6%

Be the first to know when CPRX announces revenue.

CPRX Revenue History By Year

CPRX Yearly RevenueCPRX RevenueCPRX ChangeCPRX Revenue Growth
2024-12-31$491.73M$93.53M+23.49%
2023-12-31$398.20M$184.00M+85.90%
2022-12-31$214.20M$73.37M+52.10%
2021-12-31$140.83M$21.76M+18.27%
2020-12-31$119.07M$16.77M+16.39%
2019-12-31$102.31M$101.81M+20,361.20%
2018-12-31$500.00kN/AN/A
2017-12-31$0.00N/AN/A
2016-12-31$0.00N/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A
2013-12-31$0.00N/AN/A
2012-12-31$0.00N/AN/A
2011-12-31$0.00N/AN/A
2010-12-31$0.00N/AN/A
2009-12-31$0.00N/AN/A
2008-12-31$0.00N/AN/A
2007-12-31$0.00N/AN/A
2006-12-31$0.00N/AN/A
2005-12-31$0.00N/AN/A
2004-12-31$0.00N/AN/A

1 of 2

Catalyst Pharmaceuticals Revenue FAQ

What was CPRX's revenue last quarter?

On Invalid Date, Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q3 2025 revenue of $148.39 million up 15.31% year over year. In the same quarter last year, Catalyst Pharmaceuticals's revenue was $128.70 million.

What was Catalyst Pharmaceuticals's revenue in 2024?

Catalyst Pharmaceuticals's annual revenue for the twelve months ending Dec 31, 2024 was $491.73 million, a 23.49% increase year over year.

How much does Catalyst Pharmaceuticals make in a day?

Based on Catalyst Pharmaceuticals annual revenue for the past five years, CPRX makes an average of $747,423.01 per day.

What was Catalyst Pharmaceuticals's annual revenue growth in the past year?

As of Q4 2025, Catalyst Pharmaceuticals's revenue has grown 25.56% year over year. This is 277.88 percentage points lower than the US Biotechnology industry revenue growth rate of 303.44%. Catalyst Pharmaceuticals's revenue in the past year totaled $578.20 million.

How much does Catalyst Pharmaceuticals make in a year?

Catalyst Pharmaceuticals's revenue by year for the past five years is:
  • Catalyst Pharmaceuticals's revenue for the twelve months ending Dec 31, 2024 was $491.73 million, a 23.49% increase year over year.
  • Catalyst Pharmaceuticals's annual revenue for Dec 31, 2023 was $398.20 million, a 85.9% increase from 2022.
  • Catalyst Pharmaceuticals's annual revenue for 2022 was $214.20 million, a 52.1% increase from 2021.
  • Catalyst Pharmaceuticals's annual revenue for 2021 was $140.83 million, a 18.27% increase from 2020.
  • Catalyst Pharmaceuticals's annual revenue for 2020 was $119.07 million, a 16.39% increase from 2019.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.